SphynKx: Solving the S1P riddle

SphynKx developing modulators of endogenous S1P to treat fibrosis

SphynKx Therapeutics LLC is developing a portfolio of sphingosine kinase inhibitors that can up- or down-regulate blood levels of sphingosine 1-phosphate to treat fibrosis in different organs.

The company's lead program focuses on preventing fibrosis in chronic kidney disease by increasing circulating sphingosine 1-phosphate (S1P). A less advanced program seeks to treat idiopathic pulmonary fibrosis (IPF) by lowering S1P.

S1P is a bioactive lipid involved in a host of cellular processes including cell growth, differentiation and survival. It also regulates processes that promote

Read the full 814 word article

How to gain access

Continue reading with a
two-week free trial.